Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome Business Wire Nawigacja wpisu Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration – PR Newswire Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data – Nature.com
